Detalhe da pesquisa
1.
Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US.
Oncologist
; 27(11): 907-918, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35925602
2.
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
Am J Hematol
; 97(11): E416-E419, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054316
3.
Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting.
Clin Lymphoma Myeloma Leuk
; 23(5): e222-e231, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36925388
4.
Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre- versus post-VIALE-A real-world experience from a predominantly US community setting.
Cancer Med
; 12(17): 17914-17923, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37568276
5.
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
J Manag Care Spec Pharm
; 28(9): 980-988, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35708343
6.
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Pharmacoeconomics
; 40(8): 777-790, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35696071